The announcement of new data from Incyte's oncology portfolio being presented at a major congress like ESMO is likely to generate interest among investors and could potentially lead to a positive impact on the company's stock in the short term. This is because such presentations often highlight advancements and potential growth in the company's product pipeline, which can be seen as a positive indicator of future performance.